Eli Lilly has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for Kisunla (donanemab-azbt) ...

Eli Lilly & Co. closed $48.10 short of its 52-week high ($972.53), which the company achieved on August 22nd.

Japan, with its rapidly aging population, is expected to have more than 5 million patients with dementia by 2030. Alzheimer’s ...

Eli Lilly said on Tuesday Japan's health ministry has approved donanemab, its drug for Alzheimer's disease, providing ...

The Ministry of Health, Labour and Welfare Japan approved Eli Lilly And Co’s (NYSE:LLY) Kisunla (donanemab) for adults with ...

Eli Lilly’s (NYSE:LLY) treatment for early Alzheimer's disease has been approved for use in Japan. Kisunla (donanemab-azbt), ...

An analysis of Eli Lilly's stock reveals high premium, overvaluation concerns and a low dividend yield. LLY is rated hold due ...

Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...

Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...

Eli Lilly (LLY) stock is trading near its all-time highs, with the shares only about 5% away from the record levels set in ...

Eli Lilly presents promising long-term data showing Ebglyss' efficacy in treating moderate-to-severe atopic dermatitis, with over 80% of patients maintaining clear skin for up to three years. FDA and ...

(RTTNews) - Eli Lilly and Company (LLY) Wednesday reported new long-term data for its atopic dermatitis treatment Ebglyss. The results were reported from ADjoin long-term extension study.